View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 4, 2019updated 22 Nov 2021 6:51am

Deals and M&As this week: EQT, Sanofi, Bristol-Myers Squibb

EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through the EQT VIII fund.

EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through the EQT VIII fund.

The revised bid offers Karo Skr38 ($4.23) per share.

EQT is an investment fund, while Karo Pharma is a speciality pharmaceutical company focused on developing and marketing products to pharmacies and healthcare providers.

Both companies involved in the deal are based in Sweden.

Sanofi has sold the global rights to all of its clinical development programmes that were formed as part of a collaboration agreement with MyoKardia.

The agreement was signed in 2014 for the discovery and development of drug candidates for the treatment of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Sanofi paid approximately $230m to MyoKardia as part of the agreement.

Based in France, Sanofi is a multinational pharmaceutical company, while MyoKardia is a US-based clinical-stage biopharmaceutical company focused on developing therapies for rare cardiovascular diseases.

“Aralez Pharmaceuticals has divested more than 20 medicines to Nuvo Pharmaceuticals for $110m.”

Bristol-Myers Squibb (BMS) has signed a definitive merger agreement to acquire Celgene for $74bn.

Celgene shareholders will receive one BMS share and $50 in cash per share, under the terms of the agreement.

BMS shareholders will own 69% of the combined company, while Celgene shareholders will own the remaining 31%.

Based in the US, BMS is a biopharmaceutical company, while Celgene is a biotechnology company focused on developing and commercialising medicines for cancer and inflammatory disorders.

Aralez Pharmaceuticals has divested more than 20 medicines to Nuvo Pharmaceuticals for $110m.

The transaction involved the acquisition of Aralez’s Tribute Pharmaceuticals’ Canada business and the sale of royalties and Canadian operations related to Vimovo, a therapy indicated for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Aralez Pharmaceuticals is a speciality pharmaceutical company focused on developing and commercialising cardiovascular, pain management and dermatological allergy products, while Nuvo is a commercial healthcare company.

Both firms involved in the deal are based in Canada.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU